Results 161 to 170 of about 114,090 (262)

Nonparametric maximum likelihood estimation of the survival function using current lifetime data

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract An issue when estimating the failure time survival function is how to set up a prevalent cohort study infrastructure to follow subjects after enrollment. This problem can be circumvented through the well‐known Grenander density estimator using current lifetime observations only.
James H. McVittie, Masoud Asgharian
wiley   +1 more source

Order restricted row‐column cluster randomized design

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract This research introduces a novel two‐stage cluster randomized design, the order restricted row‐column cluster randomized design. The new design builds upon the cluster randomized block design by incorporating a second layer of blocking, achieved through ranking cluster units that are randomly sampled from the population.
Dalton Hopper   +2 more
wiley   +1 more source

The life and work of Ernest Sydney Keeping

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract This article reviews the life and contributions of Ernest S. Keeping (1895–1984), a British‐born physicist who became a mathematics professor at the University of Alberta in 1929. He played a pivotal role in shaping the university's Mathematics Department, serving as its head from 1954 to 1961, and continuing to teach until 1970, nine years ...
David R. Bellhouse, Christian Genest
wiley   +1 more source

Learning sparse mixture‐of‐experts generalized linear models in ultrahigh dimensions

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract Motivated by the challenges of heterogeneity and high dimensionality in the analysis of modern data, we investigate continuous regularization methods for learning sparse mixture‐of‐experts generalized linear models (MoE‐GLM). Although there are foundational results about regularized estimators in a broad class of regression models including ...
Pengqi Liu, Abbas Khalili
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy